NASDAQ:NYXH - Nasdaq - BE0974358906 - Common Stock - Currency: USD
NASDAQ:NYXH (2/21/2025, 8:00:01 PM)
10.347
-0.05 (-0.51%)
The current stock price of NYXH is 10.347 USD. In the past month the price decreased by -0.22%. In the past year, price decreased by -39.2%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 147 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
NYXOAH SA
Rue Edouard Belin 12
Mont-Saint-Guibert BRABANT-WALLON BE
CEO: Olivier Taelman
Employees: 147
Company Website: https://www.nyxoah.com/
Phone: 3226121755
The current stock price of NYXH is 10.347 USD. The price decreased by -0.51% in the last trading session.
The exchange symbol of NYXOAH SA is NYXH and it is listed on the Nasdaq exchange.
NYXH stock is listed on the Nasdaq exchange.
14 analysts have analysed NYXH and the average price target is 15.74 USD. This implies a price increase of 52.09% is expected in the next year compared to the current price of 10.347. Check the NYXOAH SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NYXOAH SA (NYXH) has a market capitalization of 387.29M USD. This makes NYXH a Small Cap stock.
NYXOAH SA (NYXH) currently has 147 employees.
NYXOAH SA (NYXH) has a support level at 10.34 and a resistance level at 10.91. Check the full technical report for a detailed analysis of NYXH support and resistance levels.
The Revenue of NYXOAH SA (NYXH) is expected to grow by 24.94% in the next year. Check the estimates tab for more information on the NYXH EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NYXH does not pay a dividend.
NYXOAH SA (NYXH) will report earnings on 2025-03-13, after the market close.
NYXOAH SA (NYXH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).
The outstanding short interest for NYXOAH SA (NYXH) is 0.32% of its float. Check the ownership tab for more information on the NYXH short interest.
ChartMill assigns a technical rating of 6 / 10 to NYXH. When comparing the yearly performance of all stocks, NYXH is a bad performer in the overall market: 70.57% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NYXH. The financial health of NYXH is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -2.14% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -37.11% | ||
ROE | -50.6% | ||
Debt/Equity | 0.21 |
ChartMill assigns a Buy % Consensus number of 81% to NYXH. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -9.57% and a revenue growth 24.94% for NYXH